Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

8.610 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From Law Offices of Howard G. Smith
Via Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Analyst Ratings for Y-mAbs Therapeutics
 
Via Benzinga
Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
From Kahn Swick & Foti, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Kirby McInerney LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR NOTICE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Y-mAbs Class Action Lawsuit - YMAB
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
NASDAQ:YMAB Investor Alert: Investigation over Possible Securities Laws Violations by Y-mAbs Therapeutics, Inc
San Diego, CA -- (SBWIRE) -- 11/18/2022 -- Y-mAbs Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Lost Money in Y-mAbs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Lost Money in Y-mABs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Looking Into Y-mAbs Therapeutics's Recent Short Interest
Y-mAbs Therapeutics's (NASDAQ:YMAB) short percent of float has fallen 16.88% since its last report. The company recently reported that it has 3.08 million shares sold short, which is 8.47% of all... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.